Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.

Pro-urokinase represents an important addition to the array of thrombolytic drugs currently available for clinical use because of its high clot specificity but distinctly different mechanism compared with that of t-PA. Recombinant pro-urokinase (r-proUK) is a single-chain precursor of high molecular weight urokinase which has been expressed in a mouse myeloma cell line. The present study was conducted to determine the dosing regimen which would produce optimal clot lysis and restoration of blood flow 2 h after treatment with r-proUK, using a dog model of arterial thrombosis. Efficacy was indicated by lysis of a radio-labelled clot which was formed in the heat-damaged femoral arteries of 39 male beagle dogs. The animals were divided into six heparinized treatment groups, each receiving one of five dosing regimens or the vehicle for r-proUK. The total dose (80,000 U/kg) was divided into an initial loading bolus, followed by either a second bolus or by infusions for various time periods, as shown below: Group Treatment Regimen % Lysis 1 r-proUK Bolus/bolus, 50%/50% at 0 and 15 min 52 +/- 7 2 r-proUK Bolus/bolus, 50%/50% at 0 and 30 min 62 +/- 7 3 r-proUK Bolus/infusion, 20%/80% infused to 30 min 41 +/- 8 4 r-proUK Bolus/infusion, 20%/80% infused to 60 min 66 +/- 5 5 r-proUK Bolus/infusion, 50%/50% infused to 30 min 73 +/- 4 6 Vehicle Bolus/infusion, 50%/50% infused to 30 min 12 +/- 6 It was concluded that optimal clot lysis and restoration of femoral flow was accomplished using a regimen in which 50% of the dose was given as a bolus, followed immediately by the remaining 50% given as a 30 min intravenous infusion (Group 5). At the dose used in this study, r-proUK did not produce degradation of fibrinolytic or hemostatic plasma proteins.
AuthorsS E Burke, N L Lubbers, R A Nelson, J Henkin
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 77 Issue 5 Pg. 1025-30 (May 1997) ISSN: 0340-6245 [Print] GERMANY
PMID9184422 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Biomarkers
  • Fibrinolytic Agents
  • Recombinant Proteins
  • alpha-Macroglobulins
  • plasmin-alpha(2)-macroglobulin complex
  • Fibrinogen
  • Plasminogen
  • saruplase
  • Tissue Plasminogen Activator
  • Fibrinolysin
  • Urokinase-Type Plasminogen Activator
  • Animals
  • Biomarkers (blood)
  • Cell Line
  • Dogs
  • Drug Administration Schedule
  • Femoral Artery
  • Fibrinogen (analysis)
  • Fibrinolysin (analysis)
  • Fibrinolysis
  • Fibrinolytic Agents (administration & dosage, therapeutic use)
  • Hemostasis
  • Hot Temperature
  • Infusions, Intravenous
  • Injections, Intravenous
  • Male
  • Mice
  • Plasmacytoma
  • Plasminogen (analysis)
  • Recombinant Proteins (administration & dosage, therapeutic use)
  • Thrombosis (drug therapy)
  • Tissue Plasminogen Activator (therapeutic use)
  • Urokinase-Type Plasminogen Activator (administration & dosage, therapeutic use)
  • alpha-Macroglobulins (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: